ARS Pharmaceuticals downgraded by Raymond James with a new price target
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
Raymond James cut ARS Pharmaceuticals from Strong Buy to Outperform with a $17.00 price target.
Historical context for SPRY
Across the 23 sessions after earlier SPRY headlines, the stock closed higher 12 times and lower 11 times, with a median move of 3.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SPRY | SPY |
|---|---|---|---|
| Oct 29, 2026 | ARS Pharma to Report Third Quarter 2026 Financial Results | +0.3% | -0.4% |
| Sep 2, 2026 | ARS Pharmaceuticals to Participate in Upcoming Investor Conferences | +0.9% | +0.4% |
| Aug 14, 2026 | ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results | -7.4% | -0.2% |
| Aug 3, 2026 | ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results | +6.4% | +1.4% |
| Jul 8, 2026 | ARS Pharmaceuticals Announces CEO Succession | -1.1% | -0.3% |
| Jun 25, 2026 | ARS Pharmaceuticals Provides Commercial and Financial Updates | -23.9% | +0.1% |
Keep researching SPRY
- What is Analyst downgrade?A sell-side analyst's move to a less favorable rating on a stock, such as from Buy to Hold, usually published with a lower price target and rationale.
- Analyst upgrades and downgradesAn analyst upgrade or downgrade is a change in a sell-side analyst's stock rating. Learn what Buy, Hold and Sell mean, how price targets work and which changes matter.
- SPRY insider tradesEvery buy and sale reported by ARS Pharmaceuticals Inc. officers, directors and large holders.
- SPRY earnings historyPast ARS Pharmaceuticals Inc. earnings releases, newest first.
- SPRY financial statementsRevenue, profit, cash flow and balance sheet from ARS Pharmaceuticals Inc.'s SEC filings.
Quantisnow market dataNASDAQ
SPRY
ARS Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for SPRY
Full SPRY profile on Quantisnow Follow SPRY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time